NASDAQ:EVGN - Evogene Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.90 -0.04 (-2.06 %) (As of 03/22/2019 04:00 PM ET)Previous Close$1.90Today's Range$1.90 - $1.9052-Week Range$1.90 - $3.47Volume464 shsAverage Volume2,599 shsMarket Capitalization$48.93 millionP/E RatioN/ADividend YieldN/ABeta1.06 ProfileDiscussionChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. The company operates through three segments: Evogene, Evofuel, and Biomica. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. This segment develops seed traits enhancing plant yield and tolerance to abiotic stresses, such as enhanced tolerance to drought, heat, and salinity, as well as seed traits for enhancing plant resistance to biotic stresses, including resistance to diseases, pests, and insects; novel herbicides; and bio-stimulants and bio-pesticides. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Evofuel segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Biomica segment discovers and develops human microbiome-based therapeutics for the treatment of immune-mediated and infectious diseases. The company operates in the United States, Germany, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF, Corteva, ICL, Monsanto, Bayer, and others. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel. Receive EVGN News and Ratings via Email Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Agricultural chemicals Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVGN Previous Symbol CUSIPN/A CIK1574565 Webwww.evogene.com Phone972-8931-1900Debt Debt-to-Equity RatioN/A Current Ratio10.22 Quick Ratio11.86Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.75 million Price / Sales27.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.95 per share Price / Book0.97Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-20,760,000.00 Net Margins-1,188.21% Return on Equity-36.04% Return on Assets-31.63%Miscellaneous EmployeesN/A Outstanding Shares25,750,000Market Cap$48.93 million Next Earnings Date6/4/2019 (Estimated) OptionableNot Optionable Evogene (NASDAQ:EVGN) Frequently Asked Questions What is Evogene's stock symbol? Evogene trades on the NASDAQ under the ticker symbol "EVGN." How were Evogene's earnings last quarter? Evogene Ltd (NASDAQ:EVGN) issued its earnings results on Wednesday, March, 13th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.04. The biotechnology company earned $0.64 million during the quarter. Evogene had a negative return on equity of 36.04% and a negative net margin of 1,188.21%. View Evogene's Earnings History. When is Evogene's next earnings date? Evogene is scheduled to release their next quarterly earnings announcement on Tuesday, June 4th 2019. View Earnings Estimates for Evogene. Has Evogene been receiving favorable news coverage? Press coverage about EVGN stock has been trending somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evogene earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next few days. Who are some of Evogene's key competitors? Some companies that are related to Evogene include Marrone Bio Innovations (MBII), Wynnstay Group (WYN), Arcadia Biosciences (RKDA), SenesTech (SNES), China Green Agriculture (CGA), Eden Research (EDEN), Bion Environmental Technologies (BNET), Kiwa Bio-Tech Products Group (KWBT), Cavitation Technologies (CVAT), Monsanto (MON), Syngenta (SYT) and Terra Nitrogen (TNH). What other stocks do shareholders of Evogene own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evogene investors own include Teva Pharmaceutical Industries (TEVA), Portola Pharmaceuticals (PTLA), BIOLINERX LTD/S (BLRX), Nightstar Therapeutics (NITE), Protalix Biotherapeutics (PLX), Galmed Pharmaceuticals (GLMD), Novavax (NVAX), Sorrento Therapeutics (SRNE), Perrigo (PRGO) and Kamada (KMDA). Who are Evogene's key executives? Evogene's management team includes the folowing people: Mr. Ofer Haviv, CEO & Pres (Age 53)Ms. Dorit Kreiner, Interim Chief Financial OfficerMr. Mark Kapel, Exec. VP of Technology (Age 42)Dr. Eyal Emmanuel, Chief Scientific Officer (Age 46)Ms. Sigal Fattal, Exec. Officer (Age 48) Who are Evogene's major shareholders? Evogene's stock is owned by many different of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.14%). Which institutional investors are buying Evogene stock? EVGN stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC. How do I buy shares of Evogene? Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Evogene's stock price today? One share of EVGN stock can currently be purchased for approximately $1.90. How big of a company is Evogene? Evogene has a market capitalization of $48.93 million and generates $1.75 million in revenue each year. What is Evogene's official website? The official website for Evogene is http://www.evogene.com. How can I contact Evogene? Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 7612002. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected] MarketBeat Community Rating for Evogene (NASDAQ EVGN)Community Ranking: 2.3 out of 5 ( )Outperform Votes: 163 (Vote Outperform)Underperform Votes: 199 (Vote Underperform)Total Votes: 362MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/23/2019 by MarketBeat.com StaffFeatured Article: What is Cost of Goods Sold (COGS)?